topSkip to main content

Menu, Secondary

Menu Trigger


University of Rochester

The University of Rochester is one of the country's top-tier research universities. Our 158 buildings house more than 200 academic majors, more than 2,000 faculty and instructional staff, and some 11,100 students—approximately half of whom are women.

Learning at the University of Rochester is also on a very personal scale. Rochester remains one of the smallest and most collegiate among top research universities, with smaller classes, a low 10:1 student to teacher ratio, and increased interactions with faculty.

Visit the University of Rochester website.

A previously unknown component of brain anatomy acts as both a protective barrier and platform from which immune cells monitor the brain for infection and inflammation, according to University of Rochester experts.
The $15 million National Science Foundation program, I-Corps, will foster innovation and accelerate economic development in Western New York, and is a partnership with UB, Dartmouth, Cornell, University of Rochester, University of Pittsburgh, and others.
The major fusion energy breakthrough of achieving ignition is cause for celebration at Rochester’s Laboratory for Laser Energetics.
New research shows reservoirs of ocean methane in mid-latitude regions will not be released to the atmosphere under warming conditions.
Researchers at University of Rochester, University of California, Santa Barbara, and the California Institute of Technology have developed an innovative benchtop laser with potential applications in LiDAR, atomic physics, AR/VR.
Biopsies have been performed the same way since the 19th century, but new technology could enable point-of-care skin cancer diagnosis, thanks to University of Rochester researchers.
New paleomagnetic research suggests Earth’s solid inner core formed 550 million years ago and restored our planet’s magnetic field, allowing earth to avoid a Mars-like fate.
New findings about how the brain interprets sensory information may have applications for treating brain disorders and designing artificial intelligence.
Rochester biologists who study the genetics of lifespan suggest novel targets to combat aging and age-related diseases.
The University of California San Diego has joined a Phase II clinical trial to evaluate various additional COVID-19 booster shots. The trial seeks to understand if different vaccine regimens can broaden immune responses in adults who already have received a primary vaccination series and a first booster shot.